Asian stocks explode higher as AI chip fever crushes fresh oil fears
Asian markets pushed higher on Friday as investors chose the AI trade over the oil shock. Stocks rose sharply across the region
Asian markets pushed higher on Friday as investors chose the AI trade over the oil shock. Stocks rose sharply across the region
South Korea’s Kospi Index jumped by over 4% on Friday, capping a highly volatile week that saw it plunge to 7,060, its
SK Hynix’s banks earned nearly $260 million in fees from the South Korean chipmaker’s US share sale, giving Wall Street a richer
easyJet share price will be in the spotlight today as a new bid from a giant American private equity company emerged. The
Broadcom’s latest challenge to Nvidia is not another processor designed to replace its market-leading GPUs.It targets the network that enables thousands of
They may not be the obvious, high-ticket components driving the AI boom like GPUs and memory chips, but data centres’ soaring computing
OpenAI and Google have confirmed that they supplied advanced artificial intelligence services to Singapore-based subsidiaries of Alibaba, Baidu, and Tencent, companies that
Vodafone shares jumped nearly 13% on Friday. The surge came after UAE telecom operator e& agreed to sell its entire stake in
SK Hynix’s American depositary shares are set to make their Nasdaq debut after the South Korean memory-chip giant priced 177.9 million ADSs
US stock futures were mixed on Friday as investors paused after a chip-led rally and turned their attention to SK Hynix’s Nasdaq
Global investors have placed orders for more than seven times the shares available in SK Hynix’s upcoming American depositary receipt (ADR) offering,
Microsoft’s warning that the quantum-security clock is moving faster has put a beaten-down quantum stock back on Wall Street’s radar.Quantum Computing Inc.
UK housebuilders are under intense pressure this year. Barratt Redrow shares have dropped by 27%, while Taylor Wimpey, Barratt Redrow, and Persimmon
AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to achieve the primary objective